Conference Reports

European Respiratory Society (ERS) International Congress 2019

Madrid
28 September 2019 - 02 October 2019

American Thoracic Society 2019 (ATS 2019) International Conference

Dallas, Texas, US
17 May 2019 - 22 May 2019

European Lung Cancer Congress 2019 (ELCC 2019)

Geneva, Switzerland
10 April 2019 - 13 April 2019

American Thoracic Society International Conference 2018 (ATS 2018)

San Diego, California, US
18 May 2018 - 23 May 2018

European Lung Cancer Congress (ELCC) 2018

Geneva
11 April 2018 - 14 April 2018

Congress of Asian Pacific Society of Respirology (APSR 2017)

Sydney
23 November 2017 - 26 November 2017

27th International Congress of the European Respiratory Society (ERS 2017)

Milan, Italy
09 September 2017 - 13 September 2017

Malaysian Thoracic Society Annual Congress 2017

Kuala Lumpur, Malaysia
20 July 2017 - 23 July 2017
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 3 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 19 hours ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.